Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/E ratio high or low?
The P/E ratio of 45.69 is 16% below its 1-year average of 54.09, near the low end of its 1-year range (45.69–60.50).
As of 2026-10-06T22:45:37.476Z.
Calculation as of: 2026-10-06T22:45:37.476Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6e30e9273cc74abd864e2fca08a62f10ee0154e442432ff18a73c00261064cea
PE Ratio (45.69) = Close Price ($7.31) / Diluted TTM EPS ($0.16)
PE RATIO
45.69
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
25.62
median of 186 covered companies
CURRENT VS SECTOR MEDIAN
+78.34%
vs the sector median at left
Market Cap
$475.91M
PE Ratio
N/A
TTM Avg
16.90
3Y Avg
16.90
5Y Avg
16.90
Market Cap
$483.54M
PE Ratio
18.40
TTM Avg
12.02
3Y Avg
15.67
5Y Avg
102.65
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arvinas, Inc. (ARVN) | $471.65M | 45.69 | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $471.57M | N/A | 20.76 | 20.76 | 20.76 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.23M | N/A | N/A | N/A | N/A |
| Alpha Teknova, Inc. (TKNO)vs › | $469.12M | N/A | 1146.36 | 1146.36 | 1146.36 |
| Kamada Ltd. (KMDA)vs › | $467.90M | 21.40 | 21.78 | 26.84 | 31.34 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.91M | N/A | 16.90 | 16.90 | 16.90 |
| Sight Sciences, Inc. (SGHT)vs › | $465.75M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $483.54M | 18.40 | 12.02 | 15.67 | 102.65 |
| Evolus, Inc. (EOLS)vs › | $486.01M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $452.54M | 79.56 | 41.70 | 28.27 | 29.07 |
At 45.7, P/E is below its 1-year median — higher than 0% of readings in its 1-year history.
1-year low
46.3
median
54.8
1-year high
60.5
Trailing P/E
45.7
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$7.31
Forward EPS (Est.)
$-0.04
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2026-10-05 | 46.62 |
| 2026-10-02 | 46.31 |
| 2026-10-01 | 46.44 |
| 2026-09-30 | 48.37 |
| 2026-09-29 | 46.87 |
| 2026-09-28 | 46.94 |
| 2026-09-25 | 47.44 |
| 2026-09-24 | 48.69 |
| 2026-09-23 | 48.94 |
| 2026-09-22 | 53.19 |
| 2026-09-21 | 51.87 |
| 2026-09-18 | 51.81 |
| 2026-09-17 | 51.94 |
| 2026-09-16 | 51.00 |
| 2026-09-15 | 51.62 |
| 2026-09-14 | 52.50 |
| 2026-09-11 | 52.81 |
| 2026-09-10 | 54.44 |
| 2026-09-09 | 54.75 |
| 2026-09-08 | 56.75 |
| 2026-09-04 | 58.69 |
| 2026-09-03 | 58.19 |
| 2026-09-02 | 59.94 |
| 2026-09-01 | 58.00 |
| 2026-08-31 | 57.50 |
| 2026-08-28 | 57.37 |
| 2026-08-27 | 57.75 |
| 2026-08-26 | 58.25 |
| 2026-08-25 | 60.00 |
| 2026-08-24 | 58.37 |
| 2026-08-21 | 58.56 |
| 2026-08-20 | 56.44 |
| 2026-08-19 | 60.50 |
| 2026-08-18 | 57.87 |
| 2026-08-17 | 57.50 |
| 2026-08-14 | 56.06 |
| 2026-08-13 | 56.31 |
| 2026-08-12 | 55.44 |
| 2026-08-11 | 56.19 |
| 2026-08-10 | 56.19 |
| 2026-08-07 | 54.69 |
| 2026-08-06 | 54.25 |
| 2026-08-05 | 52.50 |